

CATALYST PHARMACEUTICAL PARTNERS, INC.  
Form 8-K  
March 19, 2015

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**Washington, D.C. 20549**  
**FORM 8-K**  
**CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF**  
**THE SECURITIES EXCHANGE ACT OF 1934**

Date of Report (Date of Earliest Event Reported): March 16, 2015  
**CATALYST PHARMACEUTICAL PARTNERS, INC.**

(Exact Name Of Registrant As Specified In Its Charter)

**Delaware**  
(State or other jurisdiction of  
incorporation)

**001-33057**  
(Commission File Number)

**76-0837053**  
(I.R.S. Employer

Identification No.)

**355 Alhambra Circle**

**Suite 1500**

**Coral Gables, Florida**  
(Address of principal executive offices)

**33134**  
(Zip Code)

Registrant's telephone number, including area code:  
Not Applicable

(305) 529-2522

Former Name or Former address, if changed since last report

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

.. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Edgar Filing: CATALYST PHARMACEUTICAL PARTNERS, INC. - Form 8-K

- “ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- “ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- “ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 8.01 Other Events**

On March 16, 2015, the U.S. District Court for the Southern District of Florida approved the fairness of the previously announced settlement of a class action lawsuit filed against the Company and one of its executive officers. The settlement will become effective thirty days after entry of the order. As previously announced by the Company in a Form 8-K filed on November 4, 2014, under the terms of the settlement, the Company will pay \$3.5 million in return for a settlement and release of all claims against the defendants, with the settlement amount being paid by the insurance carrier. There were no opt outs from the settlement.

In entering into the settlement, the defendants did not admit any liability, and the defendants continue to deny all of the allegations against them and maintain the suit had no merit.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

**Catalyst Pharmaceutical Partners, Inc.**

By: /s/ Alicia Grande  
Alicia Grande  
Vice President, Treasurer and CFO

Dated: March 19, 2015